Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
Depression is a common mental disorder. Its treatment with selective serotonin reuptake inhibitors (SSRIs) is effective only in a fraction of patients, and pharmacoresistance is increasing steadily. Intranasal (IN) drug delivery to the brain stands out as a promising strategy to improve current ther...
Saved in:
Main Authors: | Soraia Silva, Joana Bicker, Carla Fonseca, Nuno R. Ferreira, Carla Vitorino, Gilberto Alves, Amílcar Falcão, Ana Fortuna |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/c555d32d8b50493e9adac2c1c0e8ed7d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression
by: Soraia Silva, et al.
Published: (2021) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
by: Kishi T, et al.
Published: (2017) -
Reversed phase HPLC determination of zidovudine in rat plasma and its pharmacokinetics after a single intranasal dose administration
by: MAINARDES,RUBIANA M, et al.
Published: (2009) -
Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival
by: Marija Kosić, et al.
Published: (2022) -
Paroxetine overdose during pregnancy
by: Selin Acar, et al.
Published: (2021)